Iron Patents (Class 514/502)
-
Patent number: 11912785Abstract: Compositions of foods, vitamin and mineral supplements, topical or oral drugs, and cosmetic products containing a small peptide or peptides for slowing degradation, for example by transition metals. The peptides are di, tri, terra-, and/or penta-peptides containing two or more aspartic acid residues. The degradation of several of the vitamin and other constituents vitamin-mineral supplements can be considerably slowed by composition incorporating such peptides, particularly if soluble (and thus bioavailable) forms of copper and/or iron are also present. The peptides can be hydrolyzed by the normal digestive process thus releasing bound metals. Multiple aspartate peptide(s) compositions with foods, topical or oral drugs, cosmetic, and hair care products can replace synthetic chelating preservative agents. Methods are also described to effectively slow degradation and preserve the above products using multiple aspartate peptides.Type: GrantFiled: December 6, 2018Date of Patent: February 27, 2024Inventors: Steven W. Bailey, June E. Ayling
-
Patent number: 11814514Abstract: A thermoplastic resin composition of the present invention comprises: a rubber modified vinyl-based graft copolymer; an aromatic vinyl-based copolymer resin; zinc oxide having an average particle size of approximately 0.5-3 ?m and a specific surface area BET of approximately 1-10 m2/g; and a C10-20 alkyl phosphate. The thermoplastic resin composition has excellent weather resistance, antibacterial property, impact resistance, flowability and the like.Type: GrantFiled: December 18, 2018Date of Patent: November 14, 2023Assignee: Lotte Chemical CorporationInventors: Eun Jin Kim, Dong Hui Chu
-
Patent number: 11148990Abstract: A magnesium citrate glycinate co-salt has a formula of Mg2C8H9NO9—XH2O and a suggested structure of: The magnesium citrate glycinate co-salt has an apparent density of 1740 kg/m3 and is compressible in a range of compression pressures from approximately 50 MPa to approximately 150 MPa. The magnesium citrate glycinate co-salt is formed by combining citric acid and glycine in a 1:1 molar ratio to form an aqueous reaction mixture and neutralizing the aqueous reaction mixture with a magnesium source having a magnesium:ligand ratio of 1:1.Type: GrantFiled: December 4, 2020Date of Patent: October 19, 2021Assignee: Jost Chemical Co.Inventors: Joseph R. Hardimon, Kasey L. Morris
-
Patent number: 10813906Abstract: Disclosed herein is a method for treating infection by an enteropathogen and/or enhancing growth performance, which includes administering to a subject in need thereof a composition containing a ferrous amino acid chelate. Also disclosed herein is an animal feed containing the ferrous amino acid chelate.Type: GrantFiled: December 20, 2018Date of Patent: October 27, 2020Assignee: PROFEAT BIOTECHNOLOGY CO., LTD.Inventors: Tsun-Yuan Lin, Mu-Kuei Chen, Kai-Ting Wang, Hsun-Jin Jan
-
Patent number: 10722459Abstract: Processes for recovering colloids of carboxylate ligand modified ferric iron hydroxide materials such as IHAT (Iron Hydroxide Adipate Tartrate) are described based on the use of water miscible non-aqueous solvents, such as ethanol, methanol and acetone. The processes produce materials with advantageous properties such as improved bioavailability, reduced aggregation and/or agglomeration and/or increased iron content.Type: GrantFiled: October 7, 2016Date of Patent: July 28, 2020Assignee: United Kingdom Research and InnovationInventors: Jonathan Joseph Powell, Nuno Jorge Rodrigues Faria
-
Patent number: 10519252Abstract: Water soluble Iron carbohydrate complex obtainable from an aqueous solution of iron(III) salt and an aqueous solution of the oxidation product of one or more maltrodextrins using an aqueous hypochlorite solution at a pH-value within the alkaline range, where, when one maltodextrin is applied, its dextrose equivalent lies between 5 and 20, and when a mixture of several maltodextrins is applied, the dextrose equivalent of the mixture lies between 5 and 20 and the dextrose equivalent of each individual maltodextrin contained in the mixture lies between 2 and 40, process for its production and medicament for the treatment and prophylaxis of iron deficiency conditions.Type: GrantFiled: March 15, 2013Date of Patent: December 31, 2019Assignee: VIFOR (INTERNATIONAL) AG.Inventors: Peter Geisser, Erik Philipp, Walter Richle
-
Patent number: 10456418Abstract: The present invention provides a method for designing a ferric pyrophosphate citrate complex composition containing pyrophosphate, citrate, ferric, sodium, and sulfate ions and calculating and adjusting each salt needed based on a choice of salts that contain the above ions and a desired concentration of each ion in the final product. The present invention also provides a process for preparing a pharmaceutical dosage form of ferric pyrophosphate citrate complex composition in liquid form which is ready to be administrated to patients in need and which maintains the mass balance of ion sources throughout the process.Type: GrantFiled: October 5, 2016Date of Patent: October 29, 2019Assignee: Navinta, LLCInventors: Mahendra R. Patel, Shrenik K. Shah
-
Patent number: 10391178Abstract: The present disclosure provides a process for the preparation a premix of raltegravir potassium form 3 with excipients. This premix may be used in the manufacture of pharmaceutical formulations containing raltegravir.Type: GrantFiled: March 20, 2015Date of Patent: August 27, 2019Assignee: Mylan Laboratories LimitedInventors: Ramesh Dandala, Sivarama Prasad Vellanki, Raja Babu Balusu, Subbarayudu Putta
-
Patent number: 10377785Abstract: A method of enhancing the growth of an animal, as well as treating or preventing antimicrobial infections is provided. The method includes causing the animal to ingest or absorb an effective amount of one or more Fe III complex compounds, including but not limited to Fe III complexes comprising ligands bound to the iron center such as amino acids or ?-hydroxy acids. The compounds are also useful for inhibiting, reducing, or preventing biofilm formation or buildup on a surface; the treatment of, inhibition of growth of, and inhibition of colonization by, bacteria, both in biological and non-biological environments; disinfecting surfaces, potentiating the effects of antibiotics and other anti-microbial agents, and increasing the sensitivity of bacteria and other microorganisms, to anti-microbial agents are also provided.Type: GrantFiled: August 3, 2018Date of Patent: August 13, 2019Assignee: Akeso Biomedical, Inc.Inventors: Dlawer Ala'Aldeen, Jafar Mahdavi, Panos Soultanas
-
Patent number: 10351838Abstract: The subject matter of the present invention is in particular the use of an amino acid sequence of IDE, or of an analogue or fragment thereof, or of at least one nucleic acid sequence encoding this sequence, as a biomarker, or as an active agent, with regard to a dandruff condition of the scalp.Type: GrantFiled: December 12, 2011Date of Patent: July 16, 2019Assignee: L'OREALInventors: Caroline Delattre, Philemon Sirven, Dominique Bernard
-
Patent number: 10301339Abstract: A method of enhancing the growth of an animal, as well as treating or preventing antimicrobial infections is provided. The method includes causing the animal to ingest or absorb an effective amount of one or more Fe III complex compounds, including but not limited to Fe III complexes comprising ligands bound to the iron center such as amino acids or ?-hydroxy acids. The compounds are also useful for inhibiting, reducing, or preventing biofilm formation or buildup on a surface; the treatment of, inhibition of growth of, and inhibition of colonization by, bacteria, both in biological and non-biological environments; disinfecting surfaces, potentiating the effects of antibiotics and other anti-microbial agents, and increasing the sensitivity of bacteria and other microorganisms, to anti-microbial agents are also provided.Type: GrantFiled: September 12, 2018Date of Patent: May 28, 2019Assignee: Akeso Biomedical, Inc.Inventors: Dlawer Ala'Aldeen, Jafar Mahdavi, Panos Soultanas
-
Patent number: 9624155Abstract: This invention provides a method for producing high-purity iron(III) citrate substantially free of beta-iron hydroxide oxide, high-purity iron(III) citrate substantially free of beta-iron hydroxide oxide, and medical uses thereof.Type: GrantFiled: February 19, 2014Date of Patent: April 18, 2017Assignee: Japan Tobacco Inc.Inventors: Koji Ando, Naoki Manta
-
Patent number: 9474770Abstract: The present invention provides a sepsis therapeutic drug useful for prophylaxis and treatment of sepsis. A prophylactic agent and/or a therapeutic agent for sepsis containing 5-aminolevulinic acid (5-ALA) or a derivative thereof or a pharmacologically acceptable salt of 5-ALA or the derivative as an active ingredient is prepared. The prophylactic agent and/or the therapeutic agent preferably contains a metal-containing compound such as ferrous sodium citrate in addition to the ALAs. Preferred examples of the ALAs include ALA; various esters of ALA such as methyl, ethyl, propyl, butyl, and pentyl esters; and hydrochlorides, phosphates, sulfates of ALA and the esters.Type: GrantFiled: August 10, 2012Date of Patent: October 25, 2016Assignees: SBI Pharmaceuticals Co., Ltd., Nihon UniversityInventors: Kosaku Kinoshita, Katsuhisa Tanjoh, Akihiro Noda, Atsushi Sakurai, Tohru Tanaka, Kiwamu Takahashi, Motowo Nakajima, Fuminori Abe
-
Patent number: 9452172Abstract: An ophthalmic composition is provided, comprising chlorophyll or bacteriochlorophyll compounds for photodynamic treatment (PDT) of diseases, disorders and conditions associated with corneal or scleral anomalies, such as corneal thinning and scleral stretching.Type: GrantFiled: August 23, 2012Date of Patent: September 27, 2016Assignee: Yeda Research and Development Co. LTD.Inventors: Avigdor Joshua Scherz, Yoram Salomon, Arie Marcovich, Alexander Brandis, Daniel Wagner
-
Patent number: 9376505Abstract: A water soluble iron carbohydrate complex obtainable from an aqueous solution of iron(III) salt and an aqueous solution of the oxidation product of one or more maltrodextrins using an aqueous hypochlorite solution at a pH-value within the alkaline range, where, when one maltodextrin is applied, its dextrose equivalent lies between 5 and 20, and when a mixture of several maltodextrins is applied, the dextrose equivalent of the mixture lies between 5 and 20 and the dextrose equivalent of each individual maltodextrin contained in the mixture lies between 2 and 40, a process for its production and a medicament for the treatment and prophylaxis of iron deficiency conditions.Type: GrantFiled: July 24, 2012Date of Patent: June 28, 2016Assignee: VIFOR (INTERNATIONAL) AG.Inventors: Peter Geisser, Erik Philipp, Walter Richle
-
Patent number: 9314443Abstract: The present invention provides an agent for promoting graft survival which can suppress rejection without use of existing immunosuppressants, an organ preservation solution capable of maintaining the freshness of an organ excised from a donor, and the like. An agent for promoting graft survival or an organ preservation solution is prepared, which comprises 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of ALA or the derivative and an iron compound as active ingredients. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.Type: GrantFiled: September 12, 2012Date of Patent: April 19, 2016Assignees: National Center for Child Health and Development, SBI Pharmaceuticals Co., Ltd.Inventors: Ko Rii, Kiwamu Takahashi, Naomi Haga, Fuminori Abe, Tohru Tanaka, Motowo Nakajima, Hidenori Ito
-
Patent number: 9006170Abstract: The present invention describes therapeutic compositions comprising one or more minerals, including trivalent iron, divalent manganese and salts thereof, suitable in facilitating synthesis and deposition of connective tissue matrix, particularly rich of elastin and collagen, and mitogenic potential in human dermal fibroblasts. It also describes the phenomenon in which stimulation of elastogenesis by arterial SMC associates with a net decrease in proliferation of these cell types. The present invention also describes methods of treatment of human skin fibroblasts and arterial smooth muscle cells. The therapeutic compositions of the present invention comprise one or more of trivalent iron or divalent manganese or salts thereof and may be combined with an elastic tissue digest.Type: GrantFiled: January 12, 2010Date of Patent: April 14, 2015Assignees: Human Matrix Sciences, LLC, The Hospital for Sick ChildrenInventors: Thomas Mitts, Felipe Jimenez, Aleksander Hinek, Severa Bunda
-
Publication number: 20150079168Abstract: Methods of administering ferric citrate to reduce and/or control serum phosphorus levels, increase serum bicarbonate levels, improve one or more iron storage parameters (e.g., increase serum ferritin levels, increase transferrin saturation (TSAT), increase hemoglobin concentration) increase iron absorption, maintain iron stores, treat iron deficiency, treat anemia, reduce the need for IV iron and/or reduce the need for erythropoiesis-stimulating agents (ESAs) in chronic kidney disease patients, are disclosed.Type: ApplicationFiled: October 24, 2014Publication date: March 19, 2015Applicant: KERYX BIOPHARMACEUTICALS, INC.Inventors: Enrique Poradosu, James F. Oliviero, III, Ron Bentsur
-
Publication number: 20150065569Abstract: The present invention is related to a method for cancer treatment comprising a step of administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising ferrous amino acid chelate and a pharmaceutically acceptable carrier. By means of amino acid chelating to ferrous and maintaining chelating state through the stomach, the pharmaceutical composition in accordance with the present invention would not cause any weight variation, and is suitable for inhibiting or treating cancer.Type: ApplicationFiled: September 3, 2014Publication date: March 5, 2015Inventors: Tsun-Yuan Lin, Mu-Kuei Chen, Tsang-Tse Chen, Chai-Hui Fu, Hsun-Jin Jan, Wen-Cheng Chiu
-
Publication number: 20150057345Abstract: Method for improving the feed efficiency in poultry husbandry wherein poultry is provided with a compound directly upon hatching, the compound being selected from a lactylate in accordance with formula 1, or a Na, K, Ca, Mg, Fe(II), Zn, NH4, or Cu(II) salt thereof, R2-COO—[—CH(CH3)-COO]n-R1??Formula 1 a glycolylate of formula 2, or a Na, K, Ca, Mg, Fe(II), Zn, NH4, or Cu(II) salt thereof. R2-COO—[—CH2-COO]n-R1??Formula 2: a lactate ester of formula 3, HO—CH(CH3)-COO—R2??Formula 3: and/or a glycolic acid ester of formula 4, HO—CH2-COO—R2??Formula 4: In the above formulas R1 is selected from H, n stands for an integer with value of 1-10, and R2 stands for C1-C35 alkyl or alkenyl chain, which may be branched or unbranched. The effective compound provided to poultry is dosed level in a first part of their life-span higher than the dose level in other part of their life span.Type: ApplicationFiled: April 3, 2013Publication date: February 26, 2015Applicant: PURAC BIOCHEM BVInventors: Bart Jan Boomsma, Anne Cazemier
-
Publication number: 20150038577Abstract: A nutritional supplement for a human, the supplement having a chelate comprised of an N-acetyl-L-cysteine ligand bonded to a metal to form a chelate ring. A method for preparing a chelate comprised of N-acetyl-L-cysteine ligand and a metal having the steps of: dissolving an amount of N-acetyl-L-cysteine in an aqueous solution, adding a metal to the aqueous solution, stifling and heating the aqueous solution, and removing the solvent under reduced pressure. A method of treating a human for one or more of oxidative stress, cardiovascular disease, cerebrovascular disease, neurodegenerative diseases, Alzheimer's disease, ADHD, bipolar, schizophrenia, autism, dementia, and HIV in a human comprising administering an effective amount of a composition having N-acetyl-L-cysteine in a chelate formation with a metal. A compound having a chelate formulation with a metal being chelated by an N-acetyl-L-cysteine ligand.Type: ApplicationFiled: December 27, 2013Publication date: February 5, 2015Inventors: Xueju Xie, Rhett Sean Daniels, Patricia Gahan
-
Patent number: 8945631Abstract: Provided are: a liquid for treatment of Citrus greening disease, which is capable of curing citrus trees with Citrus greening disease; and a treatment method using the liquid. The liquid for treatment of Citrus greening disease contains Fe ions and at least some of the Fe ions are present in the form of Fe2+ ions. This treatment liquid contains a predetermined amount of Fe ions and an acid. Citrus greening disease is able to be cured by spraying the treatment liquid onto leaves of citrus trees infected with Citrus greening disease or by pouring the treatment liquid on the roots of citrus trees infected with Citrus greening disease.Type: GrantFiled: December 1, 2011Date of Patent: February 3, 2015Assignees: Hiroshima University, Aichi Steel CorporationInventors: Yoshikuni Masaoka, Makoto Usui, Tomoya Matsuyama
-
Publication number: 20150025026Abstract: Campylobacter are the commonest reported bacterial causes of gastroenteritis in the UK and industrialized worlds. This invention relates to a method of preventing or reducing the colonisation of the gastrointestinal tract of an animal with Campylobacter. Accordingly, the present invention provides a method for disinfection of an animal comprising administering to said animal at least one compound that binds to MOMP or FlaA of Campylobacter in an effective amount to reduce the number of Campylobacter present in the gastrointestinal tract of said animal. The present invention also provides a method of preventing or reducing transmission of Campylobacter from one animal to another.Type: ApplicationFiled: February 15, 2013Publication date: January 22, 2015Inventors: Jafar Mahdavi, Dlawer Ala'Aldeen
-
Publication number: 20150025138Abstract: This invention provides a method for producing high-purity iron(III) citrate substantially free of beta-iron hydroxide oxide, high-purity iron(III) citrate substantially free of beta-iron hydroxide oxide, and medical uses thereof.Type: ApplicationFiled: February 19, 2014Publication date: January 22, 2015Applicant: Japan Tobacco Inc.Inventors: Koji Ando, Naoki Manta
-
Publication number: 20140371193Abstract: This invention comprises salophene-based metallic complexes. Included are metal-chelating analogues, and method of their preparation and use. These analogues have therapeutic activity including anticancer activity.Type: ApplicationFiled: September 4, 2014Publication date: December 18, 2014Applicants: LOUISIANA STATE UNIVERSITY, WOMEN & INFANTS' HOSPITALInventors: Laurent Brard, Rakesh Singh, Satyan Kalkunte, Robert Strongin, Onur Alpturk
-
Patent number: 8895612Abstract: The present invention generally relates to treatment of iron-related conditions with iron carbohydrate complexes. One aspect of the invention is a method of treatment of iron-related conditions with a single unit dosage of at least about 0.6 grams of elemental iron via an iron carbohydrate complex. The method generally employs iron carbohydrate complexes with nearly neutral pH, physiological osmolarity, and stable and non-immunogenic carbohydrate components so as to rapidly administer high single unit doses of iron intravenously to patients in need thereof.Type: GrantFiled: December 9, 2013Date of Patent: November 25, 2014Assignee: Luitpold Pharmaceuticals, Inc.Inventors: Mary Jane Helenek, Marc L. Tokars, Richard P. Lawrence
-
Publication number: 20140343140Abstract: [Problem] To provide an agent for preventing and/or treating veisalgia. [Solution] Provided is an agent for preventing and/or treating veisalgia, the agent including an ALA (5-aminolevulinic acid).Type: ApplicationFiled: November 30, 2012Publication date: November 20, 2014Inventors: Tohru Tanaka, Motowo Nakajima, Fuminori Abe, Satofumi Kawata
-
Publication number: 20140323566Abstract: A new self-magnetic metal-salen complex compound and its derivatives are provided. The present invention is a metal-salen complex compound including any one of the following compounds.Type: ApplicationFiled: May 14, 2012Publication date: October 30, 2014Applicants: IHI CorporationInventors: Yoshihiro Ishikawa, Haruki Eguchi
-
Publication number: 20140309298Abstract: The present invention discloses a pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels.Type: ApplicationFiled: June 17, 2014Publication date: October 16, 2014Inventors: Keith CHAN, Winston Town
-
Publication number: 20140302173Abstract: A method for treating side effects of anticancer agent includes administering to a subject in need thereof a prophylactic and/or therapeutic agent containing a therapeutically effective amount of a compound shown by the following Formula (1): R1—NHCH2COCH2CH2COOR2 ??(I) wherein R1 represents a hydrogen atom or an acyl group, and R2 represents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aryl group, or an aralkyl group, or a salt thereof.Type: ApplicationFiled: October 5, 2012Publication date: October 9, 2014Applicants: NATIONAL UNIVERSITY CORPORATION KOCHI UNIVERSITY, SBI PHARMACEUTICALS CO., LTD.Inventors: Tohru Tanaka, Kyoko Tsuchiya, Masahiro Ishizuka, Motowo Nakajima, Hitoshi Nakagawa, Taro Shuin, Keiji Inoue, Hideo Fukuhara, Masayuki Tsuda, Mutsuo Furihata
-
Patent number: 8846976Abstract: The present invention discloses a novel form of ferric organic compounds, including a form of ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. The ferric organic compounds of the present invention can be delivered effectively by oral route with better delivery to treat patients suffering from hyperphosphatemia, metabolic acidosis and other disorders responsive to ferric organic compound therapy.Type: GrantFiled: August 27, 2013Date of Patent: September 30, 2014Assignee: Panion & BF Biotech Inc.Inventors: David W. K. Kwok, Nikolay Mintchev Stoynov
-
Publication number: 20140288172Abstract: A therapeutic and/or prophylactic agent for renal anemia comprising ALAs and an erythropoietin production promoter comprising ALAs.Type: ApplicationFiled: October 5, 2012Publication date: September 25, 2014Inventors: Tohru Tanaka, Motowo Nakajima, Kiwamu Takahashi, Takaaki Abe
-
Publication number: 20140288173Abstract: A method for ameliorating and/or preventing cancerous anemia includes administering to a subject in need thereof an agent containing 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt thereof. Preferably, these ALAs contain a metal-containing compound, such as sodium ferrous citrate. The above-mentioned ALAs, ALA; various esters such as ALA methylester, ALA ethylester, ALA propylester, ALA butylester, and ALA pentylester; and hydrochlorides, phosphates, and sulfates, and the like of these ALA esters are preferred examples.Type: ApplicationFiled: October 5, 2012Publication date: September 25, 2014Applicant: SBI PHARMACEUTICALS CO., LTD.Inventors: Tohru Tanaka, Motowo Nakajima, Fuminori Abe, Satofumi Kawata, Kiwamu Takahashi
-
Patent number: 8841281Abstract: The present invention relates to the fields of chemistry and pharmaceuticals. Embodiments of the present invention provide transition metal complexes of amino acids. Transition metal complexes of embodiments of the invention according to Categories I, II, III, and/or IV may be used as antimicrobial, anti-malarial, and anti-cancer agents, as well as catalysts in chemical reactions. Such compounds of the invention are particularly useful for combating multi-drug resistance against a broad range of microbials (such as MRSA and mycobacteria), including gram positive and gram negative bacteria, as well as can be used as anti-cancer agents against bladder cancer, breast cancer, colon cancer, rectal cancer, endometrial cancer, kidney cancer, leukemia, lung cancer, melanoma, non-Hodgkin's lymphoma, pancreatic cancer, prostate cancer, and thyroid cancer, to name a few.Type: GrantFiled: October 17, 2012Date of Patent: September 23, 2014Assignee: Virginia Tech Intellectual Properties, Inc.Inventor: Joseph S. Merola
-
Publication number: 20140271473Abstract: A metal ion nanocluster having a formula of X(OH)aYbZcMd(H2O)e. X, Y, Z, M, a, b, c, d, and e are defined herein. The nanocluster has a particle size of 2 to 500 nm and a molecular weight of 3500 to 1000000 Dalton. Also disclosed are a composition containing the nanocluster and a method of preparing the nanocluster.Type: ApplicationFiled: March 15, 2013Publication date: September 18, 2014Applicant: LG Bionano, LLCInventor: Chien-Chin Wu
-
Publication number: 20140256806Abstract: A method for ameliorating and/or preventing chronic kidney disease includes administering to a subject in need thereof an agent containing 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt thereof as an active ingredient. Preferably, these ALAs contain a metal-containing compound, such as sodium ferrous citrate. The above-mentioned ALAs, ALA; various esters, such as ALA methylester, ALA ethylester, ALA propylester, ALA butylester, and ALA pentylester; and hydrochlorides, phosphates, and sulfates, and the like of these ALA esters are preferred examples.Type: ApplicationFiled: October 5, 2012Publication date: September 11, 2014Applicant: SBI PHARMACEUTICALS CO., LTD.Inventors: Tohru Tanaka, Motowo Nakajima, Fuminori Abe, Satofumi Kawata, Takeo Kohda
-
Publication number: 20140249217Abstract: The present invention provides an agent for promoting graft survival which can suppress rejection without use of existing immunosuppressants, an organ preservation solution capable of maintaining the freshness of an organ excised from a donor, and the like. An agent for promoting graft survival or an organ preservation solution is prepared, which comprises 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of ALA or the derivative and an iron compound as active ingredients. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.Type: ApplicationFiled: September 12, 2012Publication date: September 4, 2014Inventors: Ko Rii, Kiwamu Takahashi, Naomi Haga, Fuminori Abe, Tohru Tanaka, Motowo Nakajima, Hidenori Ito
-
Publication number: 20140248339Abstract: A multi-component nanochain for use in diagnostic and therapeutic applications includes at least three nanoparticles linked together to form the nanochain. At least one nanoparticle of the nanochain has an asymmetric surface chemistry defined by asymmetrically disposed first linkers and second linkers. The nanoparticles are linked to form the nanochain by linking first linkers and/or second linkers disposed on separate nanoparticles.Type: ApplicationFiled: October 12, 2012Publication date: September 4, 2014Applicant: Case Western Reserve UniversityInventors: Efstathios Karathanasis, Pubudu M. Peiris, Mark Griswold
-
Publication number: 20140248342Abstract: The invention relates to iron(III) complex compounds and pharmaceutical compositions comprising them for the use in the treatment and/or prophylaxis of iron deficiency symptoms and iron deficiency anemias.Type: ApplicationFiled: May 30, 2012Publication date: September 4, 2014Applicant: Vifor (International) AGInventors: Thomas Bark, Wilm Buhr, Susanna Burckhardt, Michael Burgert, Camillo Canclini, Franz Dürrenberger, Felix Funk, Peter Geisser, Aris Kalogerakis, Simona Mayer, Erik Philipp, Stefan Reim, Diana Sieber, Jörg Schmitt, Katrin Schwarz, Jürgen Klotz
-
Publication number: 20140234437Abstract: In one of its aspects, the present invention provides a composition comprising: (i) a non-encapsulated iron salt, and (ii) a carrier comprising digestible edible oil that is a liquid at 20° C. This composition advantageously provides iron in a form that is easily administered to an infant or adult. When taken directly by mouth or added to food or infant formula, the composition has a desirably bland flavor and is easy to consume. Moreover, the high density of iron per unit volume of the composition results in a minimal volume of liquid to be administered. This makes the composition relatively innocuous and easy for infants to consume. Related aspects of the present invention are also described—e.g., uses, articles of manufacture and the like.Type: ApplicationFiled: July 5, 2012Publication date: August 21, 2014Inventor: Reinhold Vieth
-
Publication number: 20140235684Abstract: A metal-salen complex compound responsive drug, which has an antidotal property capable of neutralizing cytotoxicity of a metal-salen complex compound, and an intra-corporeal behavior control system for the metal-salen complex compound are provided. This metal-salen complex compound responsive drug contains an effective amount of a metal chelating agent to suppress side effects by the metal-salen complex compound.Type: ApplicationFiled: September 19, 2012Publication date: August 21, 2014Inventors: Yoshihiro Ishikawa, Haruki Eguchi
-
Publication number: 20140234416Abstract: Methods of administering ferric citrate to reduce and/or control serum phosphorus levels, increase serum bicarbonate levels, improve one or more iron storage parameters (e.g., increase serum ferritin levels, increase transferrin saturation (TSAT), increase hemoglobin concentration) increase iron absorption, maintain iron stores, treat iron deficiency, treat anemia, reduce the need for IV iron and/or reduce the need for erythropoiesis-stimulating agents (ESAs) in chronic kidney disease patients, are disclosed.Type: ApplicationFiled: April 25, 2014Publication date: August 21, 2014Applicant: Keryx Biopharmaceuticals, Inc.Inventors: Enrique Poradosu, James F. Oliviero, III, Ron Bentsur
-
Publication number: 20140221205Abstract: Novel actinomycete strain composition and its use.Type: ApplicationFiled: July 20, 2012Publication date: August 7, 2014Applicants: UNIVERSITE CADI AYYAD-FACULTE DES SCIENCES SEMLALIA, MARRAKESH-MAROC, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Marie-Joelle Virolle, Hanane Hamdali, Yedir Ouhdouch, Mohamed Hafidi, Ahmed Benhafrref, Ahmed Lebrihi, Marie Carmen Monje
-
Publication number: 20140206635Abstract: A metal-salen complex compound, which exhibits excellent noninvasiveness and can be efficiently transferred to an affected site, a local anesthetic containing this metal-salen complex compound, and an antineoplastic drug containing this metal-salen complex compound are provided. Regarding the metal-salen complex compound, a metal atom part in each of two molecules of a metal-salen complex or a derivative of the metal-salen complex is dimerized via water, and the metal-salen complex compound is mixed with a base to produce an ointment.Type: ApplicationFiled: May 10, 2012Publication date: July 24, 2014Applicants: IHI CORPORATIONInventors: Yoshihiro Ishikawa, Haruki Eguchi
-
Patent number: 8785475Abstract: Lipoic acid derivatives and pharmaceutical formulations containing lipoic acid derivatives are useful in the treatment and prevention of disease characterized by disease cells that are sensitive to lipoic acid derivatives.Type: GrantFiled: April 17, 2008Date of Patent: July 22, 2014Assignee: Cornerstone Pharmaceuticals, Inc.Inventors: Paul Bingham, Tom Kwok, Zuzana Zachar
-
Patent number: 8754257Abstract: The present invention discloses a pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels.Type: GrantFiled: October 26, 2012Date of Patent: June 17, 2014Assignee: Panion & BF Biotech Inc.Inventors: Keith Chan, Winston Town
-
Patent number: 8691776Abstract: A process for preparing parenteral iron-saccharidic complexes, and the complexes produced, comprising: (1) providing an aqueous solution or dispersion including (i) Fe(III) and (OH)? ions and (ii) at least one saccharide, to form a reaction mixture, where the molar ratio of (i):(ii) is about 30:1 to about 1:30; and the mixture temperature and pH are at or above the complex assembly point (CAP); and (2) maintaining temperature and pH at or above the CAP for a time sufficient to form an iron-saccharidic complex having a molecular weight of about 25,000 Daltons or more. Control of the temperature and pH efficiently produces a high molecular weight complex. The complex can be separated by precipitation, dialysis and/or column fractionation and, if desired, dried, e.g., lyophilized or spray dried. The process can controllably synthesize complexes of varying molecular weight and/or chemical composition, particularly sodium ferric gluconate and ferric hydroxide-sucrose.Type: GrantFiled: May 16, 2011Date of Patent: April 8, 2014Assignee: Chromaceutical Advanced Technologies,Inc.Inventors: Robert A. Beck, Robert A. Mateer, Jr., John Kowalski
-
Patent number: 8658193Abstract: Technologies are described herein for styptic compounds comprising a hemostatic or styptic agent suspended within a hydrophobic carrier medium. Example carrier mediums may include waxes, lipids, oils, or combinations thereof. The compound may be a semisolid at room temperature and soft enough to be easily dispensed and formed into or onto bleeding tissue of an animal or human. The hydrophobic qualities of the carrier medium can protect the styptic agent from absorbing moisture. The carrier medium can mechanically support positioning treatments adjacent to the bleeding tissue. The carrier medium can further serve to mechanically seal the tissue to aid in hemostasis while also protecting the tissue from debris and contamination. The carrier medium can aid in maintaining moisture within the tissue. Slurry-based manufacturing processes can support a substantially homogeneous dispersal of styptic agent throughout the carrier medium.Type: GrantFiled: June 8, 2012Date of Patent: February 25, 2014Inventor: Robert J. Greenwald
-
Publication number: 20140045407Abstract: The invention is in the field of bee keeping; in particular the invention relates to a composition and a method for improving winter survival of individual bees and/or bee colonies and/or for preventing colony collapse. Research at Science in Water has led to the discovery that administering iron(II) to bees under certain conditions can reduce instances of winter mortality and CCD.Type: ApplicationFiled: August 9, 2013Publication date: February 13, 2014Applicant: Science in Water B.V.Inventors: Maarten Van Hoorn, Rik Ter Horst
-
Publication number: 20140018420Abstract: The present invention discloses a novel form of ferric organic compounds, including a form of ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. The ferric organic compounds of the present invention can be delivered effectively by oral route with better delivery to treat patients suffering from hyperphosphatemia, metabolic acidosis and other disorders responsive to ferric organic compound therapy.Type: ApplicationFiled: August 27, 2013Publication date: January 16, 2014Applicant: Panion & BF Biotech, Inc.Inventors: David W.K. KWOK, Nikolay Mintchev Stoynov